Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 3/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4525755 | 0.88 | CETP (0.39) | CETPHSD11B1GPR119NR1H4KDM1A | |
| SCHEMBL1099618 | 0.88 | CETP (0.39) | CETPHSD11B1GPR119NR1H4KDM1A | |
| SCHEMBL1098050 | 0.86 | NR1H4 (0.40) | CETPHSD11B1NR1H4KDM1AHDAC8 | |
| SCHEMBL1099516 | 0.85 | CETP (0.39) | CETPHSD11B1GPR119NR1H4KDM1A | |
| SCHEMBL4525683 | 0.83 | CETP (0.38) | CETPHSD11B1GPR119NR1H4KDM1A | |
| SCHEMBL4525824 | 0.83 | CETP (0.38) | CETPHSD11B1GPR119NR1H4KDM1A | |
| SCHEMBL18617678 | 0.83 | GPR119 (0.47) | CETPHSD11B1GPR119NR1H4KDM1A | |
| SCHEMBL4521538 | 0.82 | HSD11B1 (0.45) | CETPHSD11B1NR1H4KDM1AHDAC8 | |
| SCHEMBL23027974 | 0.79 | HSD11B1 (0.44) | CETPHSD11B1NR1H4TACR1 | |
| SCHEMBL15820250 | 0.78 | HSD11B1 (0.43) | CETPHSD11B1NR1H4TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | CETP 3817/4885HSD11B1 3156/4885GPR119 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.